Accelerated atherosclerosis and inflammation in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects young women, a group usually free of atherosclerosis. As treatment for SLE has improved during recent years and long term survival increased, it has become clear that patients with SLE have increased...
Gespeichert in:
| Veröffentlicht in: | Japanese Journal of Clinical Immunology 2012, Vol.35(6), pp.470-480 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 480 |
|---|---|
| container_issue | 6 |
| container_start_page | 470 |
| container_title | Japanese Journal of Clinical Immunology |
| container_volume | 35 |
| creator | ASANUMA, Yu FUNAKUBO |
| description | Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects young women, a group usually free of atherosclerosis. As treatment for SLE has improved during recent years and long term survival increased, it has become clear that patients with SLE have increased morbidity and mortality from atherosclerotic cardiovascular disease. Several imaging techniques showed increased prevalence of premature atherosclerosis which was most striking in young patients with SLE. Pathogenesis of atherosclerosis is an inflammatory process. Inflammatory cells and mediators play a key role in the pathogenesis of atherosclerosis. Systemic inflammation and immune dysfunction are thought to accelerate atherosclerosis in patients with SLE as well. Several possible reasons for accelerated atherosclerosis in SLE have been suggested. Traditional coronary risk factors, other coronary risk factors including lipoprotein (a), CRP, homocysteine, inflammatory cytokines, increased vascular damage, lupus related factors and medications may affect the development of atherosclerosis in SLE. Atherosclerosis risk assessment, preventive strategy for accelerated atherosclerosis and its treatment would be required in patients with SLE. |
| doi_str_mv | 10.2177/jsci.35.470 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273264973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273264973</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4230-effd5173bd666b9511007071c193796c7c0e7fd2507794bd6219a39bc91f3a5e3</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhoMotmhP3mWPgmzNJNmNuQgifkHBi55DNjtrI_tRM7uH_ntTWnuZYZhnXpiHsSvgSwFa3_2QD0tZLJXmJ2wOUplcK5CnbM4NQK4k5zO2IAoV50Ldy9KYczYTUhhQ92LOVo_eY4vRjVhnblxjHMi3uxooc32dhb5pXde5MQx9GjLa0ohd8Fk7bSbKMG7TUVoPNNElO2tcS7g49Av29fL8-fSWrz5e358eV7lXQvIcm6YuQMuqLsuyMgUA55pr8GCkNqXXnqNualFwrY1KlADjpKm8gUa6AuUFu9nnbuLwOyGNtguU3mhdj8NEFoSWolRGy4Te7lGfXqKIjd3E0Lm4tcDtzqDdGbSysMlgoq8PwVPVYX1k_30l4GEP_NDovvEIuDiGpO0YVh4Sjwu_dtFiL_8AWCyDjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273264973</pqid></control><display><type>article</type><title>Accelerated atherosclerosis and inflammation in systemic lupus erythematosus</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>ASANUMA, Yu FUNAKUBO</creator><creatorcontrib>ASANUMA, Yu FUNAKUBO</creatorcontrib><description>Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects young women, a group usually free of atherosclerosis. As treatment for SLE has improved during recent years and long term survival increased, it has become clear that patients with SLE have increased morbidity and mortality from atherosclerotic cardiovascular disease. Several imaging techniques showed increased prevalence of premature atherosclerosis which was most striking in young patients with SLE. Pathogenesis of atherosclerosis is an inflammatory process. Inflammatory cells and mediators play a key role in the pathogenesis of atherosclerosis. Systemic inflammation and immune dysfunction are thought to accelerate atherosclerosis in patients with SLE as well. Several possible reasons for accelerated atherosclerosis in SLE have been suggested. Traditional coronary risk factors, other coronary risk factors including lipoprotein (a), CRP, homocysteine, inflammatory cytokines, increased vascular damage, lupus related factors and medications may affect the development of atherosclerosis in SLE. Atherosclerosis risk assessment, preventive strategy for accelerated atherosclerosis and its treatment would be required in patients with SLE.</description><identifier>ISSN: 0911-4300</identifier><identifier>EISSN: 1349-7413</identifier><identifier>DOI: 10.2177/jsci.35.470</identifier><identifier>PMID: 23291482</identifier><language>eng ; jpn</language><publisher>Japan: The Japan Society for Clinical Immunology</publisher><subject>atherosclerosis ; C-Reactive Protein - metabolism ; cardiovascular disease ; Coronary Artery Disease - epidemiology ; Coronary Artery Disease - etiology ; Coronary Artery Disease - immunology ; Coronary Artery Disease - prevention & control ; Cytokines - physiology ; Female ; Homocysteine - blood ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; inflammation ; Inflammation - complications ; Inflammation - immunology ; Inflammation Mediators - physiology ; Lipoprotein(a) - blood ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - immunology ; Male ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Sex Factors ; systemic lupus erythematosus</subject><ispartof>Japanese Journal of Clinical Immunology, 2012, Vol.35(6), pp.470-480</ispartof><rights>2012 The Japan Society for Clinical Immunology</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4230-effd5173bd666b9511007071c193796c7c0e7fd2507794bd6219a39bc91f3a5e3</citedby><cites>FETCH-LOGICAL-c4230-effd5173bd666b9511007071c193796c7c0e7fd2507794bd6219a39bc91f3a5e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23291482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ASANUMA, Yu FUNAKUBO</creatorcontrib><title>Accelerated atherosclerosis and inflammation in systemic lupus erythematosus</title><title>Japanese Journal of Clinical Immunology</title><addtitle>Jpn. J. Clin. Immunol.</addtitle><description>Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects young women, a group usually free of atherosclerosis. As treatment for SLE has improved during recent years and long term survival increased, it has become clear that patients with SLE have increased morbidity and mortality from atherosclerotic cardiovascular disease. Several imaging techniques showed increased prevalence of premature atherosclerosis which was most striking in young patients with SLE. Pathogenesis of atherosclerosis is an inflammatory process. Inflammatory cells and mediators play a key role in the pathogenesis of atherosclerosis. Systemic inflammation and immune dysfunction are thought to accelerate atherosclerosis in patients with SLE as well. Several possible reasons for accelerated atherosclerosis in SLE have been suggested. Traditional coronary risk factors, other coronary risk factors including lipoprotein (a), CRP, homocysteine, inflammatory cytokines, increased vascular damage, lupus related factors and medications may affect the development of atherosclerosis in SLE. Atherosclerosis risk assessment, preventive strategy for accelerated atherosclerosis and its treatment would be required in patients with SLE.</description><subject>atherosclerosis</subject><subject>C-Reactive Protein - metabolism</subject><subject>cardiovascular disease</subject><subject>Coronary Artery Disease - epidemiology</subject><subject>Coronary Artery Disease - etiology</subject><subject>Coronary Artery Disease - immunology</subject><subject>Coronary Artery Disease - prevention & control</subject><subject>Cytokines - physiology</subject><subject>Female</subject><subject>Homocysteine - blood</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>inflammation</subject><subject>Inflammation - complications</subject><subject>Inflammation - immunology</subject><subject>Inflammation Mediators - physiology</subject><subject>Lipoprotein(a) - blood</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Male</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Sex Factors</subject><subject>systemic lupus erythematosus</subject><issn>0911-4300</issn><issn>1349-7413</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LAzEQhoMotmhP3mWPgmzNJNmNuQgifkHBi55DNjtrI_tRM7uH_ntTWnuZYZhnXpiHsSvgSwFa3_2QD0tZLJXmJ2wOUplcK5CnbM4NQK4k5zO2IAoV50Ldy9KYczYTUhhQ92LOVo_eY4vRjVhnblxjHMi3uxooc32dhb5pXde5MQx9GjLa0ohd8Fk7bSbKMG7TUVoPNNElO2tcS7g49Av29fL8-fSWrz5e358eV7lXQvIcm6YuQMuqLsuyMgUA55pr8GCkNqXXnqNualFwrY1KlADjpKm8gUa6AuUFu9nnbuLwOyGNtguU3mhdj8NEFoSWolRGy4Te7lGfXqKIjd3E0Lm4tcDtzqDdGbSysMlgoq8PwVPVYX1k_30l4GEP_NDovvEIuDiGpO0YVh4Sjwu_dtFiL_8AWCyDjQ</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>ASANUMA, Yu FUNAKUBO</creator><general>The Japan Society for Clinical Immunology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Accelerated atherosclerosis and inflammation in systemic lupus erythematosus</title><author>ASANUMA, Yu FUNAKUBO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4230-effd5173bd666b9511007071c193796c7c0e7fd2507794bd6219a39bc91f3a5e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; jpn</language><creationdate>2012</creationdate><topic>atherosclerosis</topic><topic>C-Reactive Protein - metabolism</topic><topic>cardiovascular disease</topic><topic>Coronary Artery Disease - epidemiology</topic><topic>Coronary Artery Disease - etiology</topic><topic>Coronary Artery Disease - immunology</topic><topic>Coronary Artery Disease - prevention & control</topic><topic>Cytokines - physiology</topic><topic>Female</topic><topic>Homocysteine - blood</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>inflammation</topic><topic>Inflammation - complications</topic><topic>Inflammation - immunology</topic><topic>Inflammation Mediators - physiology</topic><topic>Lipoprotein(a) - blood</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Male</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Sex Factors</topic><topic>systemic lupus erythematosus</topic><toplevel>online_resources</toplevel><creatorcontrib>ASANUMA, Yu FUNAKUBO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese Journal of Clinical Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ASANUMA, Yu FUNAKUBO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Accelerated atherosclerosis and inflammation in systemic lupus erythematosus</atitle><jtitle>Japanese Journal of Clinical Immunology</jtitle><addtitle>Jpn. J. Clin. Immunol.</addtitle><date>2012</date><risdate>2012</risdate><volume>35</volume><issue>6</issue><spage>470</spage><epage>480</epage><pages>470-480</pages><issn>0911-4300</issn><eissn>1349-7413</eissn><abstract>Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that mainly affects young women, a group usually free of atherosclerosis. As treatment for SLE has improved during recent years and long term survival increased, it has become clear that patients with SLE have increased morbidity and mortality from atherosclerotic cardiovascular disease. Several imaging techniques showed increased prevalence of premature atherosclerosis which was most striking in young patients with SLE. Pathogenesis of atherosclerosis is an inflammatory process. Inflammatory cells and mediators play a key role in the pathogenesis of atherosclerosis. Systemic inflammation and immune dysfunction are thought to accelerate atherosclerosis in patients with SLE as well. Several possible reasons for accelerated atherosclerosis in SLE have been suggested. Traditional coronary risk factors, other coronary risk factors including lipoprotein (a), CRP, homocysteine, inflammatory cytokines, increased vascular damage, lupus related factors and medications may affect the development of atherosclerosis in SLE. Atherosclerosis risk assessment, preventive strategy for accelerated atherosclerosis and its treatment would be required in patients with SLE.</abstract><cop>Japan</cop><pub>The Japan Society for Clinical Immunology</pub><pmid>23291482</pmid><doi>10.2177/jsci.35.470</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0911-4300 |
| ispartof | Japanese Journal of Clinical Immunology, 2012, Vol.35(6), pp.470-480 |
| issn | 0911-4300 1349-7413 |
| language | eng ; jpn |
| recordid | cdi_proquest_miscellaneous_1273264973 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | atherosclerosis C-Reactive Protein - metabolism cardiovascular disease Coronary Artery Disease - epidemiology Coronary Artery Disease - etiology Coronary Artery Disease - immunology Coronary Artery Disease - prevention & control Cytokines - physiology Female Homocysteine - blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage inflammation Inflammation - complications Inflammation - immunology Inflammation Mediators - physiology Lipoprotein(a) - blood Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - immunology Male Randomized Controlled Trials as Topic Risk Assessment Risk Factors Sex Factors systemic lupus erythematosus |
| title | Accelerated atherosclerosis and inflammation in systemic lupus erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A08%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Accelerated%20atherosclerosis%20and%20inflammation%20in%20systemic%20lupus%20erythematosus&rft.jtitle=Japanese%20Journal%20of%20Clinical%20Immunology&rft.au=ASANUMA,%20Yu%20FUNAKUBO&rft.date=2012&rft.volume=35&rft.issue=6&rft.spage=470&rft.epage=480&rft.pages=470-480&rft.issn=0911-4300&rft.eissn=1349-7413&rft_id=info:doi/10.2177/jsci.35.470&rft_dat=%3Cproquest_cross%3E1273264973%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273264973&rft_id=info:pmid/23291482&rfr_iscdi=true |